Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04260217
Recruitment Status : Recruiting
First Posted : February 7, 2020
Last Update Posted : July 12, 2021
Sponsor:
Information provided by (Responsible Party):
Ascentage Pharma Group Inc.

Tracking Information
First Submitted Date  ICMJE February 5, 2020
First Posted Date  ICMJE February 7, 2020
Last Update Posted Date July 12, 2021
Actual Study Start Date  ICMJE May 30, 2021
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 5, 2020)
  • Primary Toxicity Endpoint: dose limiting toxicity (DLT) [ Time Frame: 42 days ]
    DLT will be defined based on the rate of drug-related grade 3-5 adverse events experienced within the first 6 weeks (2 cycles) of study treatment. These will be assessed via CTCAE version 5.0
  • Maximally tolerated dose (MTD) [ Time Frame: 42 days ]
    MTD will be determined based on DLTs observed during the first 6 weeks (2 cycles) of study treatment
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
Official Title  ICMJE A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)
Brief Summary Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.
Detailed Description

This is an open-label, multi-center Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab. The study consists of the dose escalation and the dose expansion phases. The clinical trial will have multiple arms with ability to subsequently add more treatment arms based upon clinical activity of APG2575 in WM. Initially the study will contain 3 arms noted below, all the arms are independent.

Arm A: APG-2575 will be administered as a single agent to determine the MTD/RP2D in subjects who are relapsed/resistant or intolerant to ibrutinib or other BTK inhibitors.

The Dose escalation phase of APG-2575 as monotherapy will use mTPI-2 design. The starting target dose (using ramp-up if needed) is 400 mg (dose level; DL1) and will be increased to 600 mg (DL2), 800 mg (DL3) accordingly. Doses can be increased to higher level depending on safety and PK results based on discussions of the Investigators and Sponsor. APG-2575 will be administered orally once daily until time of progression or unacceptable toxicity. After the MTD/RP2D is determined, up to 12 additional patients will be enrolled at RP2D in dose-expansion phase to further evaluate safety and efficacy of APG-2575.

Arm B: APG-2575 will be administered in combination with ibrutinib in subjects with previously untreated WM.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
APG2575 400 mg ramp up arm
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Waldenstrom Macroglobulinemia
Intervention  ICMJE
  • Drug: APG2575 400 mg
    APG2575 400 mg
  • Drug: APG2575 600 mg
    APG2575 600 mg
  • Drug: APG2575 800 mg
    APG2575 800 mg
Study Arms  ICMJE
  • Experimental: APG2575 400 mg
    APG2575 400mg ramp up arm
    Interventions:
    • Drug: APG2575 400 mg
    • Drug: APG2575 600 mg
    • Drug: APG2575 800 mg
  • Experimental: APG2575 600 mg
    APG2575 600 mg ramp up arm
    Interventions:
    • Drug: APG2575 600 mg
    • Drug: APG2575 800 mg
  • Experimental: APG2575 800 mg arm
    APG2575 800 mg arm ramp up
    Intervention: Drug: APG2575 800 mg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 5, 2020)
96
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 30, 2022
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Criteria for inclusion:

Patients must meet all of the following inclusion criteria to be eligible for participation in this study:

  1. Local confirmed clinicopathological diagnosis of WM in accordance with the consensus panel of the Second International Workshop on WM (Owen 2003).
  2. WM patients with symptomatic and measurable disease (defined as presence of serum immunoglobulin M (IgM)>0.5g/dL), requiring treatment as per mSMART guidelines (Kyle 2003): with B symptoms (fever, night sweats, fatigue, night sweats weight loss), progressive lymphadenopathy or splenomegaly, anemia (hemoglobin value of <10 g/dL) or platelet count <100*109/L due to marrow infiltration. Complications such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy due to WM, systemic amyloidosis related to WM, renal insufficiency related to WM, or symptomatic cryoglobulinemia may also be indications for therapy.
  3. For Arm A only: Have received at least one prior therapy for WM. Patient must have either failed (defined as progressing while on or within 6 months of treatment with ibrutinib treatment) or intolerant to ibrutinib.
  4. For Arm B only: Previously untreated WM.
  5. For Arm C only: Have received at least one prior therapy, relapsed or refractory WM.
  6. Adequate hematologic function defined as:

    1. ANC ≥1.0 x 109/L independent of growth factor support within 7 days of the first dose with study drug.
    2. Hemoglobin ≥9 g/dL without transfusion or growth factor support within 7 days of the first dose of study drug.
    3. Platelet count ≥ 75 x 109/L without transfusion support within 7 days of the first dose of study drug.
  7. Adequate hepatic and renal function defined as:

    1. AST and ALT < 2.5 x ULN (upper limit of normal)
    2. Glomerular filtration rate (GFR) >30mL/min
    3. Bilirubin< 1.5 x ULN
  8. PT/INR ≤1.5 x ULN and PTT (aPTT) ≤1.5 x ULN.
  9. ≥18 years of age.
  10. Eastern Cooperative Oncology Group (ECOG) ≤1.
  11. Life expectancy≥3 months.
  12. Female subjects who are of non-reproductive potential (i.e., post-menopausal by history-no menses for ≥2 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.
  13. Male and female subjects who agree to use highly effective methods of birth control (e.g.,condoms, implants, injectables, combined oral contraceptives, some intrauterine devices[IUDs], sexual abstinence, or sterilized partner) during the period of therapy and for 30 days after the last dose of study drug and 90 days (males) after the last dose of study drug.

Symptomatic disease meeting at least 1 of the recommendations from the Second International Workshop on Waldenström Macroglobulinemia for requiring treatment (Kyle 2003):

  1. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as one or more of the following disease-related symptoms or signs:

    1. Unintentional weight loss ≥10% within the previous 6 months prior to Screening
    2. Fevers higher than 100.5°F or 38.0°C for 2 or more weeks prior to Screening without evidence of infection
    3. Night sweats for more than 1 month prior to Screening without evidence of infection
  2. Clinically relevant fatigue which is not relieved by rest due to WM
  3. Symptomatic hyperviscosity or serum viscosity levels greater than 4.0 centipoises
  4. Lymphadenopathy which is either symptomatic or bulky (≥5cm in maximum diameter)
  5. Symptomatic hepatomegaly and/or splenomegaly and/or organ tissue infiltration
  6. Peripheral neuropathy due to WM
  7. Symptomatic cryoglobulinemia
  8. Cold agglutinin anemia
  9. IgM related immune hemolytic anemia and/or thrombocytopenia
  10. Nephropathy related to WM
  11. Amyloidosis related to WM
  12. Hemoglobin ≤10g/dL
  13. Platelet count <100 x109/L
  14. Serum monoclonal protein >5g/dL, with or without overt clinical symptoms.
  15. Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.

Exclusion Criteria:

  • Criteria for exclusion:

Patients who meet any of the following exclusion criteria are not to be enrolled in this study:

  1. For Arm A only: Patients who have never been treated with ibrutinib.
  2. For Arm B only: Patients who have previously received any treatment for WM.
  3. For Arm C only:

    1. Patients who have previously been treated with ibrutinib or other BTK inhibitor.
    2. Disease that is refractory to the last prior rituximab based-therapy defined as either Relapse after the last rituximab-based therapy (<12 months since last dose of rituximab), OR Failure to achieve at least a MR after the last rituximab-based therapy.
    3. Rituximab treatment within the last 12 months before the first dose of study drug.
    4. Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab.
  4. Patients with central nervous system involvement (Bing-Neel syndrome), active infection (including active hepatitis B or C virus infection, known human immunodeficiency virus (HIV) positive) or any other serious (unresolved) medical condition.
  5. Plasmapheresis <35 days prior to the initiation of study drug. (Note: Subjects with high IgM values or hyper-viscosity symptoms during screening may receive plasmapheresis prior to initiating study drug if the previous plasmapheresis was performed >35 days before the plasmapheresis performed during screening (in order to obtain a true baseline IgM value for efficacy evaluations).
  6. Failure to have fully recovered (i.e., ≤Grade 1 toxicity) from the reversible effects of prior treatment for WM.
  7. Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block type II, 3rd degree block, or corrected QT interval (QTc) ≥470 msec.
  8. Unable to swallow tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  9. History of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) defined by positive polymerase chain reaction (PCR).
  10. Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
  11. Major surgical procedure within ≤14 days prior to initiating study treatment, or anticipation of the need for major surgery during the course of the study treatment, radiotherapy ≤14 days prior to initiating study treatment, systemic treatment within 14 days before the first dose of APG-2575.
  12. Recent infection requiring systemic treatment that was completed≤14 days before the first dose of study drug.
  13. Any uncontrolled active systemic infection.
  14. Any concurrent malignancy.
  15. Concomitant use of warfarin or other Vitamin K antagonists (eg. phenoprocoumon).
  16. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
  17. Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.
  18. History of stroke or intracranial hemorrhage within 12 months prior to enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 95 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Angela Kaiser 310-509-0357 angela.kaiser@ascentage.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04260217
Other Study ID Numbers  ICMJE APG2575WU101
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ascentage Pharma Group Inc.
Study Sponsor  ICMJE Ascentage Pharma Group Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Ascentage Pharma Group Inc.
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP